Corcept Therapeutics (CORT) Stock Price, News & Analysis

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CORT shares.
View CORT analyst ratings or view top-rated stocks.

4 equities research analysts have issued twelve-month price objectives for Corcept Therapeutics' stock. Their CORT share price targets range from $31.00 to $47.50. On average, they anticipate the company's share price to reach $40.10 in the next year. This suggests a possible upside of 42.8% from the stock's current price.
View analysts price targets for CORT or view top-rated stocks among Wall Street analysts.

Corcept Therapeutics' stock was trading at $32.48 at the start of the year. Since then, CORT shares have decreased by 13.5% and is now trading at $28.09.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our CORT earnings forecast.

Corcept Therapeutics Incorporated (NASDAQ:CORT) released its earnings results on Wednesday, May, 1st. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.21 by $0.04. The biotechnology company earned $146.80 million during the quarter, compared to analyst estimates of $141.19 million. Corcept Therapeutics had a trailing twelve-month return on equity of 24.19% and a net margin of 22.38%. Corcept Therapeutics's revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.14 earnings per share.

ETFs with the largest weight of Corcept Therapeutics (NASDAQ:CORT) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), First Trust NYSE Arca Biotechnology Index Fund (FBT), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO) and ETC 6 Meridian Small Cap Equity ETF (SIXS).

Corcept Therapeutics updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $610.6 million.

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

Corcept Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.19%), Norden Group LLC (1.92%), Ikarian Capital LLC (0.00%), Jupiter Asset Management Ltd. (0.72%), Jacobs Levy Equity Management Inc. (0.70%) and Kynam Capital Management LP (0.00%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, G Leonard Baker, Jr, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff, Sean Maduck and William Guyer.
View institutional ownership trends.

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.